Can be galectin-3 a novel marker in determining mortality in hemodialysis patients?(Retracted article. See vol.49,pg.942,2016)

OZKAN, Gulsum; ULUSOY, ŞÜKRÜ; MENTEŞE, AHMET; GÜVERCİN, BEYHAN; KARAHAN, SÜLEYMAN; YAVUZ, Adnan; ALTAY, Diler; OCAL, Mustafa

doi:10.1016/j.clinbiochem.2015.05.003

Can be galectin-3 a novel marker in determining mortality in hemodialysis patients?(Retracted article. See vol.49,pg.942,2016)

Copy For Citation

OZKAN G., ULUSOY Ş., MENTEŞE A., GÜVERCİN B., KARAHAN S. C., YAVUZ A., ...More

CLINICAL BIOCHEMISTRY, vol.48, no.12, pp.768-773, 2015 (SCI-Expanded)

Publication Type: Article / Article
Volume: 48 Issue: 12
Publication Date: 2015
Doi Number: 10.1016/j.clinbiochem.2015.05.003
Journal Name: CLINICAL BIOCHEMISTRY
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Page Numbers: pp.768-773
Karadeniz Technical University Affiliated: Yes

Abstract

Background: Cardiovascular (CV) mortality is common in hemodialysis (HD) patients. There are some difficulties involved in determining CV risk. Galectin-3 is a molecule with a demonstrated correlation with CV mortality and which is approved in the stratification of heart failure (HF) risk. The purpose of this study was to assess the previously uninvestigated relationship between galectin-3 and cardiac mortality in HD patients.